The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Self-citationBertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704
Caturegli, P., Newschaffer, C., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 588
Self-citationFaje, A. T., Sullivan, R., Lawrence, D., Tritos, N. A., Fadden, R., Klibanski, A., & Nachtigall, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2306 · Cited by 479
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Faje, A. (2016) · Pituitary · doi:10.1007/s11102-015-0671-4 · Cited by 326
Albarel, F., Gaudy, C., Castinetti, F., Carré, T., Morange, I., Conte-Devolx, B., Grob, J.-J., & Brue, T. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0845 · Cited by 289
CTLA4 gene polymorphism and autoimmunity
Gough, S. C. L., Walker, L. S. K., & Sansom, D. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00249.x · Cited by 288
Min, L., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Luke, J. J., Donahue, H., Davis, M., Carroll, R. S., & Kaiser, U. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2353 · Cited by 274
IgG4-Related Hypophysitis: A New Addition to the Hypophysitis Spectrum
Leporati, P., Landek-Salgado, M. A., Lupi, I., Chiovato, L., & Caturegli, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2970 · Cited by 267
Self-citationBasis of CTLA-4 function in regulatory and conventional CD4+ T cells
Tai, X., Van Laethem, F., Pobezinsky, L., Guinter, T., Sharrow, S. O., Adams, A., Granger, L., Kruhlak, M., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 251
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M. N., Whitelaw, B. C., Palomar, M. T. P., Wu, Y., & Carroll, P. V. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 220
Tsunoda, A., Okuda, O., & Sato, K. (1997) · PubMed · Cited by 176
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2016) · Future Oncology · doi:10.2217/fon.15.222 · Cited by 147
Breunis, W. B., Tarazona‐Santos, E., Chen, R., Kiley, M., Rosenberg, S. A., & Chanock, S. J. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817fd8f3 · Cited by 109
Effect of cancer treatment on hypothalamic–pituitary function
Crowne, E. C., Gleeson, H. K., Benghiat, H., Sanghera, P., & Toogood, A. A. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00008-x · Cited by 84
Immune Checkpoint Inhibitor Therapy Associated Hypophysitis
Mahzari, M. M., Liu, D., Arnaout, A., & Lochnan, H. A. (2015) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s22469 · Cited by 59
Szczerba, B. M., Kapłonek, P., Wolska, N., Podsiadłowska, A., Rybakowska, P., Dey, P., Rasmussen, A., Grundahl, K. M., Hefner, K. S., Stone, D. U., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206297 · Cited by 54
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
Barzey, V., Atkins, M. B., Garrison, L. P., Asukai, Y., Kotapati, S., & Penrod, J. R. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.739226 · Cited by 52
Xanthomatous hypophysitis: A novel entity of obscure etiology
Deodhare, S. S., Bilbao, J. M., Kovács, K., Horváth, É., Nomikos, P. V., Buchfelder, M., Reschke, K., & Lehnert, H. (1999) · Endocrine Pathology · doi:10.1007/bf02738885 · Cited by 50
Economic burden of toxicities associated with treating metastatic melanoma in eight countries
Wehler, E., Zhao, Z., Bilir, S. P., Munakata, J., & Barber, B. (2015) · The European Journal of Health Economics · doi:10.1007/s10198-015-0757-y · Cited by 49
From Japan With Love: Another Tessera in the Hypophysitis Mosaic
Caturegli, P., & Iwama, S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1912 · Cited by 41
Self-citationAutoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade
Gutenberg, A., Landek‐Salgado, M. A., Tzou, S., Lupi, I., Geis, A. L., Kimura, H. J., & Caturegli, P. (2009) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.37 · Cited by 22
Self-citationZheng, G., Chaux, A., Sharma, R. B., Netto, G. J., & Caturegli, P. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.05.008 · Cited by 12
Self-citationTiu, C., Pezaro, C., Davis, I. D., Grossmann, M., & Parente, P. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12348 · Cited by 5
Cited by
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Metadata
- Authors
- Caturegli, P., Di Dalmazi, G., Lombardi, M., Grosso, F., Larman, H. B., Larman, T., Taverna, G., Cosottini, M., & Lupi, I.
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 186
- Issue
- 12
- Pages
- 3225-3235
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2533633657
- Cited by
- 381
- References
- 30
- FWCI
- 26.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.